vidarabine has been researched along with Cells, Neoplasm Circulating in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bodzenta-Lukaszyk, A; Bolkun, L; Dabrowska, M; Eljaszewicz, A; Jasiewicz, M; Kaminski, K; Kloczko, J; Lapuc, I; Luksza, E; Miklasz, P; Moniuszko, M; Piszcz, J; Ptaszynska-Kopczynska, K; Rusak, M; Singh, P | 1 |
| Champlin, RE; Couriel, D; de Lima, M; de Souza, J; Giralt, S; Komanduri, KV; Oran, B; Patah, P; Rondon, G; Saliba, RM | 1 |
| Björkstrand, B; Gruber, A; Johnsen, HE; Pelliniemi, TT; Rasmussen, T; Remes, K | 1 |
| Keating, MJ; Moufarij, MA; Plunkett, W; Sampath, D | 1 |
| Barth, S; Borchmann, P; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Reiser, M; Schinköthe, T; Schulz, H; Tur, M; Wessels, J | 1 |
3 trial(s) available for vidarabine and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Female; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Leukemia, Myeloid, Acute; Lymphocytes; Male; Melphalan; Middle Aged; Neoplastic Cells, Circulating; Transplantation Conditioning; Transplantation, Homologous; Tumor Burden; Vidarabine | 2009 |
Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clone Cells; Cytarabine; Dexamethasone; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplastic Cells, Circulating; Remission Induction; Vidarabine; Vincristine | 2003 |
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Adducts; DNA Repair; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Vidarabine | 2006 |
2 other study(ies) available for vidarabine and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.
Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Count; Cell Lineage; Cyclophosphamide; Female; Flow Cytometry; GPI-Linked Proteins; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Neoplastic Cells, Circulating; Receptors, Cell Surface; Receptors, IgG; Rituximab; Vidarabine | 2015 |
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Topics: Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Computer Systems; DNA, Neoplasm; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Cells, Circulating; Polymerase Chain Reaction; Rituximab; Vidarabine | 2002 |